Loading
Life sciences · Journal article
Blood Advances · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Survivors of childhood cancer are at risk of adverse sequelae related to prior therapies. We describe the prevalence of and risk factors for late (≥5 years from cancer diagnosis) venous thromboembolism (VTE) among participants of the St. Jude Lifetime Cohort (N=5229). Prevalence of late VTE was compared between survivors and community controls (N=737) without a history of childhood cancer. Associations with treatment and clinical factors were assessed in multivariable regression models. Ninety-four (1.8% 95% CI 1.5-2.2%) survivors [median age at cancer diagnosis 9.4 years (range:0.0-20.9); 38.5 years (12-65.9) at evaluation] had 108 VTEs vs. 5 (0.7% 95% CI 0.2%-1.6%) among controls (p=0.02) (31.1 years [12.1-70.2] at evaluation). The cumulative incidence 35 years from diagnosis was highest among survivors of Hodgkin lymphoma (7.6% [95% CI 4.5%-11.8%]). Fifty-eight of 108 (53.7%) were in an extremity (upper=7, lower=51) followed by pulmonary (38, 35.2%), abdomen (n=5, 4.6%), neck (n=3, 2.8%), cerebral sinus (n=1, 0.9%), other (n=3, 2.8%). No associations with early (<5 years from cancer diagnosis) VTE were identified (p=0.7). In adjusted models, late VTE was associated with exposure to chest (OR 2.0 95% CI 1.01-4.0) and abdominal (OR 2.2 95% CI 1.04-4.8) radiation, not combined radiation fields (OR 1.2 95% CI 0.7-2.0), and sex hormone use (OR 2.2 95% CI 1.2-3.7). The prevalence of and risk for VTE are elevated among survivors of childhood cancer, particularly those treated with radiation or using sex hormones. Incorporating these factors into risk assessments may guide monitoring, prophylaxis, or interventions, particularly in high-risk situations.